Clinical e-news
The newsletter designed to keep the FibroScan® community up-to-date on clinical news and resources.
The following articles are the latest clinical peer-reviewed publications on liver health management.
In this European multicenter study of patients with cACLD, predominantly due to metabolic diseases, SSM by VCTE® at 100 Hz significantly improved non-invasive diagnosis of CSPH compared to standard methods. The comprehensive model (NICER) incorporating SSM, LSM, platelet count, and BMI establishes a new standard for CSPH risk stratification, enhancing access to disease-modifying treatments for these patients.
The FIB-4 score / VCTE® algorithm showed excellent diagnostic performance, demonstrating its applicability for routine screening in diabetology.
- Effective Screening: A two-step strategy (FIB-4 score followed by VCTE®) effectively identifies patients at high risk of advanced fibrosis.
- Noninvasive Test Performance: FIB-4 outperformed NFS and MAF-5, with a high negative predictive value (97.2%) for ruling out advanced fibrosis.
- Referral to Specialized Care: The FIB-4/VCTE® strategy led to appropriate referrals for hepatology care, though 2% of referrals were false positives.
- Practical for Clinics: The two-step approach is practical and effective for identifying high-risk patients in diabetology and nutrition clinics.
This cross-sectional study from Sweden demonstrated that screening for liver fibrosis using VCTE® during routine retina scans in people with type 2 diabetes is highly accepted and feasible, with over half showing metabolic dysfunction-associated steatotic liver disease and 7.4% confirmed with significant fibrosis.
The objective of this study was to review clinical evidence on clinical utility and to establish consensus guidelines for non-invasive tests, in assessing liver fibrosis in people living with alpha-1 antitrypsin deficiency.
VCTE® represents a particularly valuable approach for post-Fontan patients, given the increased procedural risks associated with invasive liver assessment in this population.
The objective of this study was to evaluate the relationship between LSM by VCTE® and FALD, establish diagnostic cut-off values for FALD and advanced FALD, and assess the correlation between LSM and clinically significant outcomes.
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) affects 1 in 4 people globally, with particularly high rates among those with type 2 diabetes, where 2 in 3 have fatty liver and up to 38% develop advanced fibrosis or cirrhosis. Since 2024, updated European guidelines recommend a two-step screening approach: a simple blood test (FIB-4) followed by Liver Stiffness Measurement (LSM) by FibroScan® device to identify high-risk patients.
This study tested the algorithm on over 1,000 adults with type 2 diabetes who visited a diabetes clinic. Those with a result suggesting increased liver risk received further testing, including imaging and, when needed, liver biopsy. The study evaluates the systematic implementation of the EASL-EASD screening algorithm within a real-world diabetology clinic setting.
With new drug treatments emerging for MASLD, there is an urgent clinical need for simple, widely available, non-invasive tools that can identify patients at risk of disease progression and monitor their response to therapy. This study evaluated whether 1-year changes in FibroScan®-derived data: liver stiffness measurement (LSM) and controlled attenuation parameter (CAP), alongside FIB-4 and serum ALT, can predict liver-related outcomes in patients with MASLD and serve as practical non-invasive tools to guide and monitor pharmacological treatment decisions.